---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010426"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:10:50.984497+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma gets FDA Pre-IND feedback on oral CC-42344 for influenza A

## Summary
- Received FDA Pre-IND written response to January 2024 submission for oral CC-42344.
- Guidance clarifies regulatory requirements for planned Phase 2b trial design.
- Phase 2a challenge study in UK ongoing; topline results expected H2 2024.
- Preparations underway for inhaled CC-42344 Phase 1 study in Australia.
- Inhaled formulation showed superior lung exposure and favorable safety in preclinical data.

## SEC filing metadata
- accession: 0001493152-24-010426
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224010426/0001493152-24-010426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224010426/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010426
- JSON: https://secwatch.observer/filing/0001493152-24-010426.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.